MHRA approves EURneffy nasal spray for childhood anaphylaxis
The MHRA has approved EURneffy, an adrenaline nasal spray, for treating anaphylaxis in children. The 1mg dose formulation gives younger children access to a needle-free treatment option for the first time in the UK.
What happened
The MHRA granted approval for EURneffy, an intranasal adrenaline spray, for use in children experiencing anaphylaxis. The approved dose is 1mg. Until now, adrenaline for anaphylaxis in the UK has been delivered by injection — typically via an auto-injector device. EURneffy changes that by offering a needle-free route of administration.
Why it matters
Anaphylaxis is a life-threatening allergic reaction requiring immediate treatment. Adrenaline is the first-line intervention, and speed of administration matters. Auto-injectors have long been the standard, but they can be difficult to use correctly under stress — and for younger children, a nasal spray may be easier for caregivers and school staff to administer quickly and accurately.
For pharmacy practice, this approval has real day-to-day implications. Pharmacists dispensing allergy management plans, counselling patients and families on emergency medication, or completing medicines use reviews will now need to be familiar with EURneffy alongside existing auto-injector options. When a parent or carer comes in asking about their child's anaphylaxis kit, you need to know what this product is, how it differs from an auto-injector, and what the 1mg dose means in context.
There's also a supply and stock angle. Community pharmacies will need to anticipate demand as prescribers begin reaching for EURneffy for appropriate patients. Understanding the product's licensed indication — specifically that it is approved for children — helps you flag any prescribing queries correctly.
GPhC exam relevance
The GPhC Common Registration Assessment tests clinical knowledge and the ability to apply it in practice. Anaphylaxis management sits firmly within that scope. The assessment may present scenarios involving emergency medication, allergy history, or patient counselling, and knowing the full range of available treatments — including newer options like EURneffy — is part of being assessment-ready.
More broadly, the exam expects candidates to demonstrate they can act on current evidence and updated options, not just default to older treatments. A question framed around a child's anaphylaxis kit, a prescriber query, or a patient asking whether their existing auto-injector is still appropriate could all touch on knowledge of what's now licensed.
Adrenaline pharmacology is also fair game. Knowing the mechanism — alpha and beta-adrenergic agonist activity reversing bronchospasm, vasodilation, and urticaria — remains as relevant as ever regardless of the route of administration.
What's next
Watch for EURneffy appearing in clinical guidance updates and on approved formularies. As prescribers become familiar with the product, dispensing queries will follow. It's worth checking the MHRA product information for EURneffy directly to understand the licensed age range and any storage or handling requirements before the product reaches your dispensary.
If you're on placement in a community or GP-linked pharmacy, ask whether the practice or pharmacy has updated its anaphylaxis protocols to reflect the new option. That kind of proactive awareness is exactly what the GPhC expects of a registered pharmacist.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/clinical/mhra-approves-new-nasal-spray-for-anaphylaxis-in-children-DMSGHTY2ABDLJILHXC42SJOWQE/